Transient paradoxical bronchospasm associated with inhalation of the LAMA AZD9164: analysis of two Phase I, randomised, double-blind, placebo-controlled studies

BMC Pulmonary Medicine

Ulf Sjöbring¹  Kerstin Strandgården¹  Thomas Bengtsson²  Carin Jorup¹ 

[1] AstraZeneca R&D Mölndal, Pepparedsleden 1, 431 83 Mölndal, Sweden;StatMind AB, Scheelevägen 2 1, 223 81 Lund, Sweden

关键词: Tolerability;    Safety;    Pharmacodynamics;    Pharmacokinetics;    Bronchodilator;    COPD;    Long-acting;    Muscarinic;    LAMA;   

Others  :  863155
DOI  :  10.1186/1471-2466-14-52

 received in 2013-03-28, accepted in 2014-03-19,  发布年份 2014

【 摘 要 】

Background

AZD9164 has demonstrated potential as an inhaled, long-acting, muscarinic antagonist (LAMA) bronchodilator. However, in patients with COPD, but not in healthy subjects, a transient initial drop in FEV₁ was observed following inhalation of nebulised doses of AZD9164 in citrate buffer.

Two additional studies were conducted to further assess the safety and tolerability of multiple ascending doses of AZD9164 in 27 white and 18 Japanese healthy subjects and in 4 patients with COPD. In these studies, AZD9164 was inhaled via Turbuhaler™.

Methods

These were Phase I, randomised, double-blind, placebo-controlled, multiple ascending dose (MAD) studies conducted in Sweden and UK. Healthy subjects (mean age 25.9 yrs) and patients with COPD (mean age 66 yrs, mean post-bronchodilator FEV₁ 60.1% predicted normal value) were randomised 2:1 to active treatment (400, 1000 or 2800 μg delivered doses of AZD9164) or placebo.

Results

No safety or tolerability concerns were identified in the healthy subjects at doses up to and including 2800 μg and both studies confirmed the bronchodilator effect of AZD9164. However, the first 3 patients in the COPD cohort who received AZD9164 (1000 μg) experienced a transient fall in FEV₁ 5 to 15 minutes after inhalation of AZD9164 while the patient receiving placebo did not. The study safety review process then resulted in cessation of further activities on AZD9164. Retrospective analysis showed that two healthy subjects had also had transient falls in FEV₁ shortly after inhalation of AZD9164 400 and 2800 μg respectively, although neither reported any related respiratory symptoms or other AEs.

Conclusions

These results show that transient paradoxical bronchoconstriction can occur in some healthy subjects, in addition to patients with COPD, following inhalation of AZD9164 and that the citrate buffer used in the nebulised formulation cannot have been the only cause of the drop in FEV₁ in previous studies. As preclinical data do not provide an explanation, the reasons for this brief post-dose drop in FEV₁ remain unclear. However, these results highlight the importance of monitoring lung function immediately post-dose when investigating novel inhaled treatments, even when a rapid onset of effect is not expected.

Trial registration

Clinicaltrials.gov NCT01016951 and NCT01096563.

【 授权许可】

   
2014 Jorup et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Barnes PJ: Chronic obstructive pulmonary disease: a growing but neglected global epidemic. PLoS Med 2007, 4:e112.
• [2]Pauwels R, Rabe KF: Burden and clinical features of chronic obstructive pulmonary disease (COPD). Lancet 2004, 364(9434):613-620.
• [3]Barnes PJ, Shapiro SD, Pauwels RA: Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur Respir J 2003, 22:672-688.
• [4]Vogelmeier C, Hederer B, Glaab T, Schmidt H, Rutten-van Mölken M, Beeh KM, Rabe KF, Fabbri LM: Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med 2011, 364:1093-1103.
• [5]Yohannes AM, Willgoss TG, Vestbo J: Tiotropium for treatment of stable COPD: a meta-analysis of clinically relevant outcomes. Respir Care 2011, 56:477-487.
• [6]Santus P, Di Marco F: Safety and pharmacological profile of tiotropium bromide. Expert Opin Drug Saf 2009, 8:387-395.
• [7]Tashkin DP: Impact of tiotropium on the course of moderate-to-very severe chronic obstructive pulmonary disease: the UPLIFT trial. Expert Rev Respir Med 2010, 4:279-289.
• [8]ZuWallack AR, ZuWallack RL: Tiotropium bromide, a new, once-daily inhaled anticholinergic bronchodilator for chronic-obstructive pulmonary disease. Expert Opin Pharmacother 2004, 5:1827-1835.
• [9]Bjermer L, Bengtsson T, Jorup C, Lötvall J: Local and systemic effects of inhaled AZD9164 compared with tiotropium in patients with COPD. Respir Med 2012, 107:84-90.
• [10]Barnes PJ: The pharmacological properties of tiotropium. Chest 2000, 117:63S-66S.
• [11]Fryer DA, Jacoby DB: Muscarinic Receptors and Control of Airway Smooth Muscle. Am J Respir Crit Care Med 1998, 158:S154-S160.
• [12]Belmonte KE: Cholinergic pathways in the lungs and anticholinergic therapy for chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005, 2:297-304.
• [13]Nicklas RA: Paradoxical bronchospasm associated with the use of inhaled beta agonists. J Allergy Clin Immunol 1990, 85:959-964.
• [14]Seed MJ, Agius RM: Paradoxical asthma hazard of short-acting b2-agonists. Allergy 2008, 63:241.
• [15]Beasley CRW, Rafferty P, Holgate ST: Bronchoconstrictor properties of preservatives in ipratropium bromide (Atrovent) nebuliser solution. Brit Med J 1987, 294:1197-1198.
• [16]Hodder R, Pavia D, Lee A, Bateman E: Lack of paradoxical bronchoconstriction after administration of tiotropium via Respimat® Soft Mist™ Inhaler in COPD. Int J COPD 2011, 6:245-251.
• [17]Mutlu GM, Moonjelly E, Chan L, Olopade CO: Laryngospasm and paradoxical bronchoconstriction after repeated doses of beta 2-agonists containing edetate disodium. Mayo Clin Proc 2000, 75:285-287.
• [18]Gupta P, O’Mahoney MS: Potential adverse effects of bronchodilators in the treatment of airways obstruction in older people: recommendations for prescribing. Drugs Aging 2008, 25:415-443.
• [19]Suzuki S, Miyashita A, Matsumoto Y, Okubo T: Bronchoconstriction induced by spirometric manoeuvres in patients with bronchial asthma. Ann Allergy 1990, 65:315-320.
• [20]Israel RH, Kohan JM, Poe RH, Kallay MC, Greenblatt DW, Rathbun S: Inhaled metaproterenol is superior to inhaled cromolyn in protecting against cold-air-induced bronchospasm. Respiration 1988, 53:225-231.